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Özet
Amaç: Hematolojik kanser (HK) öyküsü olan hastalarda böbrek taşı için yapı-
lan perkütan nefrolitotomi (PNL) operasyonunun sonuçlarını incelemek. Ge-
reç ve Yöntem: Merkezimizde, 2000-2013 yılları arasında böbrek taşı tedavi-
si için 1700 erişkin hasta PNL operasyonuna girmiştir. 4 hasta HK öyküsüne 
sahipti ve bunlar HK grubu olarak çalışmaya alındı (n=4). Operasyon öyküsü, 
HK veya herhangi bir komorbid hastalık öyküsü bulunmayan 10 ileri yaşlı has-
ta (>65 yaş) kontrol grubu olarak seçildi (n=10). Cerrahi parametreler, başa-
rı oranları, ek tedavi gereksinimleri ve komplikasyonlar değerlendirildi. Bulgu-
lar: İstatistiksel analizler; taş büyüklüğü, operasyon süresi, floroskopi süresi, 
hastanede kalış süresi, ∆Hb, kan transfüzyon oranları ve INR değerleri açısın-
dan HK ve kontrol grup arasında anlamlı bir fark göstermedi (p>0.05). İstatis-
tiksel analizler; başarı oranları açısından HK ve kontrol grup arasında anlamlı 
bir fark göstermedi (p=0.470). İstatistiksel analizler; ek tedavi gereksinimleri 
açısından HK ve kontrol grup arasında anlamlı bir fark göstermedi (p=0.882). 
Her iki grupta da major perioperatif komplikasyon gözlenmedi. Tartışma: He-
matolojik kanser öyküsü olan böbrek taşı hastalarının PNL ile tedavisi uygu-
lanabilir, güvenli ve etkilidir. Bununla beraber, operayon öncesinde Hematolo-
ji bölümü ile yakın kooperasyon gerekmektedir. 
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Abstract
Aim: To define the alterations in the outcomes of percutaneous nephroli-
thotomy (PNL) operations for kidney stones in patients with history of hema-
tological malignancy (HM). Material and Method: Between 2000 and 2013, 
1700 adult patients underwent PNL for the treatment of kidney stones in 
our institution. Four of these patients had a history of HM and considered 
to be HM group (n=4). Ten elderly (>65 years) patients who had no history 
of operation, HM or any other co-morbide diseases were chosen as the con-
trol group (n=10). Surgical parameters, success rates, additional treatments 
and complications were evaluated. Results: Statistical analyses showed no 
significant differences between HM and control group according to stone 
area, operation time, fluoroscopy time, hospitalization time, ∆Hb, blood 
transfusion rates and INR values (p>0.05). Statistical analyses revealed no 
significant differences between HM and control groups according to the suc-
cess rates (p=0.470). Statistical analyses revealed no significant difference 
between groups for additional treatment requirements (p=0.882). No major 
perioperative complication was seen in both of the groups. Discussion: The 
treatment of kidney stone disease by PNL in patients with hematological 
malignancy is feasible, safe and effective. However, close cooperation with 
the Hematology Department before the operation is mandatory. 
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Introduction   
Progress in the minimally invasive treatment of kidney stones 
has enabled urologists to successfully treat patients with co-
morbid diseases such as diabetes mellitus, hypertension and 
obesity.  Hematological malignancies (HM) are also serious co-
morbid diseases that comprise a collection of heterogeneous 
conditions, all originating from cells of the bone marrow and 
the lymphatic system. HM represented three major groups; leu-
kemias, lymphomas, and plasma cell neoplasms[1]. In the United 
States of America, HM represented nearly 106,200 new cases 
in 2003, it is considered as the second most common cause 
of cancer deaths, affected approximately 57,000 people in the 
same year [1]. The operative risk of patients with malignant he-
matological disorders is increased, as this may include coagula-
tion defects, changes in blood viscosity, immune suppression 
and bone narrow insufficiency [2]. When surgically treating these 
patients, the surgeon must be concerned about postoperative 
infection, hemorrhage and leukaemic transformation. Surgical 
trauma, because of its immune-depressing effects, have the po-
tential risk of increasing the hematological problems, leading to 
fatal or morbid complications [3]. The outcomes of percutane-
ous nephrolithotomy (PNL) procedures in this subset of patients 
have not been documented in the surgical literature yet. 
In this study, we retrospectively analyzed the results of PNL 
operations in the treatment of kidney stones in patients with 
history of hematological malignancy. We also compared the 
surgical parameters and outcomes with a control group. The 
aim of the study was to define the alterations in the outcomes 
of PNL operations for kidney stones in patients with history of 
hematological malignancy. 
Material and Method
Patients: Between 2000 and 2013, 1700 adult patients under-
went PNL for the treatment of kidney stones in our institution. 
Four of these patients had a history of HM and considered to 
be HM group (n=4). In this group, 2 of the patients had Non-
Hodgin’s Lymphoma (NHL), one of them Hodgin’s Lymphoma 
(HL) and one of them chronic myeloid leukemia (CML). Three of 
the patients in HM group were initially treated by chemotherapy 
regimens according to the protocols of Hematology Depart-
ment in our institution and were considered to be at remission 
period. The other patient in HM group was diagnosed as NHL 
just before the PNL operation and decided to be treated six 
weeks after the operation by the Hematology Department since 
he was considered to be suitable for the operation according 
to the blood cell counts and had no risk of bleeding diathesis. 
Among 1700 patients, 10 elderly (>65 years) patients had no 
history of operation, HM or any other co-morbide diseases; 
thus, they were considered to be the control group (n=10). We 
preferred elderly patients in order to eliminate the age factor 
among groups, since the HM group was consist of patients old-
er than 57 years. The kidney stones were diagnosed by intrave-
nous pyelography (IVU) and/or computerized tomography (CT). 
Stones that fill the renal pelvis and all calyces were defined as 
staghorn calculi. In order to calculate the total stone area, the 
area of each stone part located in the calyces and the pelvis 
was calculated seperately and then added. The area of each 
stone part was calculated by multiplying the largest vertical and 
horizontal diameter in millimeters as seen on a plain radiogram.
Prior to the operation the patients were consulted with the He-
matology Department and were hospitalized for the regulation 
of bleeding diathesis, blood cell counts and international nor-
malized ratio (INR), as necessary. Coagulation parameters were 
intensively evaluated. Patients with urinary tract infection were 
treated by culture specific antibiotic treatment before surgery. 
All patients were treated with short term prophylactic antibiot-
ics treatment. Intensive medical care facilities were also pro-
vided liberally after the operation. 
Operations: All of the operations were performed in a single 
center under general anesthesia. After ureteral catheterization 
in lithotomy position, the patients were tilted to prone position. 
The pyelocalyceal system was approached with the insertion of 
an 18-gauge Chiba needle under fluoroscopic guidance. Tract 
dilation was achieved either via Amplatz or balloon dilators 
(MarFlow®, Switzerland) after placement of a safety guide-wire 
in place. At the end of dilation a 30 F renal sheath was placed 
and nephroscopy was performed. A pneumatic lithotripter was 
used for stone fragmentation. The stone fragments were me-
chanically extracted. A 16 F re-entry nephrostomy catheter was 
placed at the end of the operation. Operation time was derived 
from the anesthesia chart and defined as the time elapsed in 
minutes from the induction of anesthesia until the insertion 
of nephrostomy catheter. The difference of hemoglobin (∆Hb) 
calculated by subtracting the hemoglobin value after surgery 
from the value before surgery was used for the evaluation of 
blood loss. Postoperative outcome was evaluated using a plain 
X-ray performed on the morning after procedure and CT at the 
follow-up. The success rate of the operation was evaluated in 
three categories; stone free (SF), clinically insignificant residual 
fragments (CIRF, residual fragments smaller than 4 mm) and 
clinically significant residual fragments (CSRF, residual frag-
ments larger than 4 mm. For the patients who required addi-
tional treatment for stone clearance after PNL, the type and 
the outcome of additional treatment was recorded. The neph-
rostomy catheter was withdrawn after antegrade pyelography 
in the second day after surgery and/or after the gross hematu-
ria cleared. Hospitalization time was defined as the number of 
days the patient spent at the hospital starting from the day of 
surgery. 
The surgical parameters, outcomes and complications were 
compared between the HM and control group.
Statistical analyses: To perform a t-test for independent groups, 
two assumptions have to be satisfied by the data. These as-
sumptions are for each variable, the sampling distribution of 
differences between group means is normally distributed and 
homogeneity of variances for groups. Since our data did not 
fully satisfy these assumptions for some of the variables we 
performed non-parametric test to compare groups with respect 
to the variables. Also, since data has small numbers of obser-
vations (total n=14) and includes some outliers we preferred 
to apply non-parametric statistical analysis techniques to the 
data. As nonparametric test; Mann-Whitney U test was used to 
compare medians of two independent samples and Chi-square 
test was performed to test of independence between two vari-
ables. We also used Fisher’s Exact Test when 2 cells (50%) have 
expected count less than 5.
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Results
There were 3 males and 1 female in HM and 8 males and 2 fe-
males in the control groups, respectively. PNL was performed to 
3 (75%) left and 1 (25%) right kidneys in HM group, and 7 (70%) 
left and 3 (30%) right kidneys in the control group. In one of 
the patients in HM group who was in remission period of CML, 
the preoperative activated partial thromboplastin time (APTT), 
prothrombin time (PT) and INR were slightly higher, thus, 57.9 
seconds, 15.6 seconds and 1.5 respectively. The Hematology 
Department offered to treat with 200 ml of fresh frozen plasma 
(FFP) 12 hours before the operation, thus the APTT, PT and INR 
values of the patients became to normal range as 38.5 seconds, 
14.3 seconds and 1.2, respectively. Also, they suggested blood 
transfusion in order to increase the hematocrit level up to 28% 
before the operation since our patient’s preoperative level was 
24%. Therefore, 2 units of erythrocyte suspension was trans-
fused to the patient, thus the hematocrit level became 33.4%, 
preoperatively. In one of the patient in HM group who was re-
cently diagnosed as NHL (diffuse large B cell ) by lymph node 
biopsy, the Hematology Department requested PNL operation 
for left kidney stone prior to chemotherapy regimen in order 
to relief the obstruction. The patient underwent 7 episodes of 
chemotherapy regimen consist of 650 mg Rituximab, 1300 mg 
cyclophosphamide, 85 mg doxorubicin, 2 mg vincristine 6 weeks 
after the operation. In two other patients in HM group who were 
in remission period of HL and NHL, there weren’t any altera-
tions in coagulation parameters or hematological values, thus 
no special treatment modality was offered by Hematology De-
partment preoperatively. The mean age, stone area, operation 
time, fluoroscopy time, ∆Hb, blood transfusion rates, hospital 
stay time and INR values for both of the groups and the cor-
responding p values are presented in Table 1. Statistical analy-
ses showed no significant differences between HM and control 
group according to operation parameters except age thus the 
mean age in control group was significantly higher than the HM 
group (p=0.002). Preoperative and postoperative white blood 
cell (WBC) counts and platelet counts were at normal range in 
both HM and control groups. In HM group, the mean difference 
of preoperative and postoperative WBC counts was 1740±1200 
K/mm3. The access numbers of the groups were presented in 
Table 2. The success rates for both of groups are presented in 
Table 3. Statistical analyses revealed no significant differences 
between HM and control groups according to the success rates 
(p=0.470). In the HM group, 1 (25%) patient with CSRF required 
extracorporeal shock wave lithotripsy (SWL) as an additional 
treatment after PNL.  The patient became stone free after one 
session SWL. At 3 months follow-up in the HM group 3 (75%) 
patients became stone free, 1 (25%) had CIRF. In the control 
group, 2 (20%) of the patients required SWL as additional treat-
ment after PNL. Both of the patients became stone free after 
two sessions of SWL for each. Three (30%) of the patients who 
had CIRF were followed without any treatment. At 3 months 
follow-up in the control group 7 (70%) of the patients became 
stone free, 3 (30%) had CIRF. Statistical analyses revealed no 
significant difference between groups for additional treatment 
requirements (p=0.882). The stone analysis revealed whew-
ellite-weddellite stone in the 2 of the patients while uric acid 
stone in the other 2 of the patients in HM group. Stone analysis 
was not mentioned in any of the patients in control group. 
No major perioperative complication was seen except blood 
transfusions in 3 of the patients in control group (Grade II, Cla-
vien Classification of Surgical Complications) 
[4]. 
Discussion
The European Association of Urology (EAU) 
Guidelines recommend PNL treatment for the 
kidney stones larger than 20 mm within the 
pelvis and lower or middle or upper calices, 
also 10-20 mm within the lower calices when 
the unfavourable factors exist for SWL [5]. 
Several improvements and modifications have 
helped to decrease the morbidity of PNL in-
cluding regional blocks, single step dilatations, 
miniperc and microperc techniques, tubeless 
PNL and sandwich therapy [6-9]. The improvements in the tech-
nique and increase in the experience of the urologists provide 
more regular, effective and safer treatment of kidney stone dis-
ease with PNL. Consequently, PNL has also become one of the 
main treatment modalities for kidney stones of patients with 
co-morbid diseases including diabetes mellitus, hypertension, 
obesity and impaired renal function [10, 11]. The treatment of 
kidney stones by PNL operation in patients with HM also re-
quires special consideration. Because, the surgical trauma have 
the potential risk of increasing the hematological problems, 
postoperative infection, hemorrhage and leukaemic transfor-
mation leading to fatal or morbid complications [3]. Therefore, 
Table 1. The operation parameters according to groups
Parameters HM Group
(mean±standart deviation, range)
Control Group
(mean±standart deviation, range)
p 
values
Age 60±2.2 years, (57-62) 70±3.8 years, (66-76)  0.002
Stone area 950±300 mm2 , (600-1200) 1025±230 mm2, (550-1350)  0.776
Operation time 100±38.2 min, (40-120) 135±38.5 min, (90-210)  0.070
Flouroscopy time 1.9±1.1 min, (0.4-2.4) 3.7±2.2 min, (2-9.7)  0.126
∆Hb 0.9±0.5 gr/dl, (0.3-1.5) 2.0±1.8 gr/dl, (0-5.1)  0.240
Transfusion rate 0 30%  0.505
INR 1.038±0.09, (1-1.3) 1.0±0.0, (1)  0.660
Hospitalization time 3.9±2.3 days, (3-4) 3.9±1.1 days, (2-12)  0.999
Table 2. Number of accesses according to groups
Number of Access HM Group (n) Control group (n)
1 access 4 (100%) 8 (80%)
2 accesses 0 2 (20%)
3 accesses 0 0
Intercostal access (11-12th rib) 0 1 (10%)
Table 3. The success rates of groups
Success rate HM Group Control Group
SF 2 (50%) 5 (50%)
CIRF 1 (25%) 3 (30%)
CSRF 1 (25%) 2 (20%)
F 0 0
SF: Stone free, CIRF: Clinically insignificant residual fragments, CSRF: Clinically 
significant residual fragments, F: failure
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surgical strategy in patients with HM must be planned and 
carried out with the specific aim of decreasing postoperative 
complications. Previous reports concerning cardiac surgery in 
patients with HM demonstrated infection as the primary cause 
of morbidity [2, 12-15]. Some studies showed morbidity rates 
of between 23 and 57%. Samuels et al. [12] reported the inci-
dence of infectious complications as 42%, underlining the ma-
jor role they play in the hospital stay [14]. Some investigations 
emphasised the use of additional intravenous immunoglobulin, 
as broad-spectrum antibiotic prophylaxis was found to be in-
sufficient to prevent or control infection in these patients [12]. 
Bleeding is another potential complication in this group of pa-
tients. Fecher et al. reported a 16.6% rate of bleeding and it 
was the main postoperative complication they observed [14]. 
Finally, the prior reports cited the complication rate between 23 
an 57% [12-14]. They concluded that long-term perioperative 
multidisciplinary follow up and adequate medical treatment are 
essential in prolonging survival [15].
PNL experience in HM patients with kidney stone is limited and 
there has been no study reported in the literature yet. In the 
present study, we evaluated the surgical parameters and out-
comes of PNL operations in HM patients with kidney stones and 
compared with control group. In the 1700 consecutive patients 
who underwent PNL at our institution, 4 patients (0,25%) had 
a history of HM diagnosed by Hematology Department. Three 
of the patients in HM group were initially treated by chemo-
therapy regimens according to the protocols of Hematology 
Department in our institution and were considered to be at re-
mission period.  The control group was consist of 10 elderly 
patients who were treated by PNL operation for kidney stone 
and had no history of operation, HM or any other co-morbide 
diseases.  The insignificant difference between HM and control 
groups among stone area and INR levels reflects the homogen-
ity of the groups (p>0.05). The mean age of the control group 
was statistically higher than the HM group (p=0.002). We espe-
cially preferred the elderly patients as a control group in order 
to eliminate the age affect. The insignificant difference between 
the groups according to the surgical parameters such as opera-
tion time, fluoroscopy time, ∆Hb, blood transfusion rates and 
hospital stay time reflects that hematological malignancy did 
not negatively affect the performance of the PNL operations 
(p>0.05). Although it didn’t reach statistically significance, the 
operation and flouroscopy time was shorter, the change in the 
Hb level and transfusion rate was lower in HM group. This might 
be due to the conservative approach of the surgeons because of 
the oversensitivity to the patients with known HM. The shorter 
flouroscopy time in HM group might also be due to the surgeon 
experience since it was observed that higher experience has 
statistically significant effect on the duration of fluoroscopy in 
PNL operations [16]. Statistical analyses revealed no significant 
differences between the groups according to the success rates 
(p=0.470) and additional treatment requirements (p=0.882). 
Thus, HM did not negatively affect the outcomes of the PNL 
operation in patients with kidney stones. 
Although the general opinion on cardiac surgery is that it does 
not exacerbate HM in patients in the remission period, a prob-
able increase in WBC count after the surgery may stimulate a 
leucomoid reaction, which can lead to a relapse in an otherwise 
quiescent illnes [15, 17]. Since the rate of septic shock after PNL 
operations has been reported as 2.4% in the literature and pre-
operative urine WBC count and operation time >90 minutes are 
two significant risk factors, the HM patients in the remission 
period prior the PNL surgery still have the risk for complication 
[18]. However, in our study the surgical trauma didn’t lead any 
increase the hematological problems or leukaemic transforma-
tion although a slight increase in WBC count after the operation. 
But, the surgeon should be aware of the potential risk of septic 
shock and indirectly leucomoid reaction after the PNL operation 
especially in the HM patients with increased preoperative WBC 
count and longer than 90 minutes of operation time.
Also, no other perioperative complication was seen in the pa-
tients with HM. 
However, there are some limitations of the present study. First-
ly, this is a retrospective study. Secondly, the patient number in 
the HM group is quite low. This is due to the lower insidance 
of HM with kidney stone in a single centre. A multicentre study 
with higher patient numbers might be more confidental.
Conclusion
The treatment of kidney stone disease by PNL in patients with 
hematological malignancy is feasible, safe and effective. How-
ever, close cooperation with the Hematology Department to 
achieve optimal health condition before the operation, maxi-
mum precision to the principles of PNL surgery and availability 
of postoperative intensive care, are of utmost importance in the 
management of this group of patients. We hope that our study 
might establish a basis for further studies with higher patient 
volume in the future.
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